Vimizim (elosulfase alfa)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- elosulfase alfa
- Company
- BioMarin International Limited
- Status
- Authorised
- Therapeutic area
- Mucopolysaccharidosis IV
- EU approval
- Sun 27 Apr 2014
- Designations
- Additional monitoring
- Application
- EMEA/H/C/002779
- ATC
- A16AB12
- Official record
- www.ema.europa.eu
Indication
Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.
Regulatory milestones
No milestones recorded in the last year.
Follow Vimizim
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.